NMT1 and neoplasm: The approach was complemented by complementary information available from our in house HLA ligand database, which contains an array of natural HLA ligands presented on various different tumor entities (including CRCs) and benign tissues (n = 132 and n = 82 for HLA class I and HLA class II ligands, respectively, including NML and NMT).